Chordia Therapeutics,IncJP:190A
| Aug 31, 2022 | Aug 31, 2023 |
---|
Profit (loss) before income taxes | -1,777 | 226 |
---|
Depreciation | 3 | 6 |
---|
Share issuance costs | 25 | - |
---|
Subsidy income | -39 | -8 |
---|
Decrease (increase) in prepaid expenses | 5 | 13 |
---|
Decrease (increase) in advance payments to suppliers | 151 | -22 |
---|
Decrease (increase) in long-term prepaid expenses | 1 | -7 |
---|
Increase (decrease) in accounts payable - other | 45 | 108 |
---|
Increase (decrease) in provision for bonuses | -2 | -8 |
---|
Other, net | -130 | 228 |
---|
Subtotal | -1,718 | 536 |
---|
Subsidies received | 16 | 10 |
---|
Income taxes paid | -2 | -2 |
---|
Net cash provided by (used in) operating activities | -1,704 | 544 |
---|
Purchase of property, plant and equipment | -9 | -0 |
---|
Purchase of intangible assets | -5 | -0 |
---|
Other, net | -1 | 1 |
---|
Net cash provided by (used in) investing activities | -15 | 0 |
---|
Proceeds from issuance of shares | 3,976 | - |
---|
Net cash provided by (used in) financing activities | 3,976 | - |
---|
Net increase (decrease) in cash and cash equivalents | 2,257 | 544 |
---|